Halozyme Therapeutics Valuation
| HALO Stock | USD 39.12 0.15 0.38% |
At this time, the firm appears to be overvalued. Halozyme Therapeutics retains a regular Real Value of $32.25 per share. The prevalent price of the firm is $39.12. Our model calculates the value of Halozyme Therapeutics from evaluating the firm fundamentals such as Current Valuation of 6.14 B, return on asset of 0.12, and Return On Equity of 2.22 as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors encourage obtaining undervalued assets and abandoning overvalued assets since, at some point, asset prices and their ongoing real values will come together. Key fundamental drivers impacting Halozyme Therapeutics' valuation include:
Price Book 58.5485 | Enterprise Value 6.1 B | Enterprise Value Ebitda 13.431 | Price Sales 5.9156 | Forward PE 12.6263 |
Overvalued
Today
Please note that Halozyme Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Halozyme Therapeutics is based on 3 months time horizon. Increasing Halozyme Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Halozyme Therapeutics is useful when determining the fair value of the Halozyme stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Halozyme Therapeutics. Since Halozyme Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Halozyme Stock. However, Halozyme Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 39.12 | Real 32.25 | Target 51.9 | Hype 38.97 | Naive 38.3 |
The real value of Halozyme Stock, also known as its intrinsic value, is the underlying worth of Halozyme Therapeutics Company, which is reflected in its stock price. It is based on Halozyme Therapeutics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Halozyme Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Halozyme Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Halozyme Therapeutics helps investors to forecast how Halozyme stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Halozyme Therapeutics more accurately as focusing exclusively on Halozyme Therapeutics' fundamentals will not take into account other important factors: Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Halozyme Therapeutics' intrinsic value based on its ongoing forecasts of Halozyme Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Halozyme Therapeutics' closest peers. When choosing an evaluation method for Halozyme Therapeutics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.
Halozyme Therapeutics Investments |
|
Halozyme Valuation Trend
Knowing Halozyme Therapeutics' actual value is paramount for traders to make sound investment determinations. Halozyme Therapeutics' real value is not only important for the investor to make better decisions but also for a more accurate overall view of Halozyme Therapeutics' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Halozyme Therapeutics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
Halozyme Market Cap
Halozyme Therapeutics is rated below average in market capitalization category among related companies. Market capitalization of Health Care industry is currently estimated at about 167.22 Billion. Halozyme Therapeutics holds roughly 4.95 Billion in market capitalization claiming about 2.96% of equities under Health Care industry.Halozyme Therapeutics Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Halozyme Therapeutics's current stock value. Our valuation model uses many indicators to compare Halozyme Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Halozyme Therapeutics competition to find correlations between indicators driving Halozyme Therapeutics's intrinsic value. More Info.Halozyme Therapeutics is rated # 2 in price to earning category among related companies. It is rated # 2 in price to book category among related companies fabricating about 0.97 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Halozyme Therapeutics is roughly 1.03 . As of the 24th of April 2024, Price To Book Ratio is likely to drop to 55.27. Comparative valuation analysis is a catch-all model that can be used if you cannot value Halozyme Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Halozyme Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Halozyme Therapeutics' earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Halozyme Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Halozyme Therapeutics and how it compares across the competition.
About Halozyme Therapeutics Valuation
The stock valuation mechanism determines the current worth of Halozyme Therapeutics on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Halozyme Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Halozyme Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Halozyme Therapeutics's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Halozyme Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Halozyme Therapeutics. We calculate exposure to Halozyme Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Halozyme Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 636.9 M | 668.7 M | |
| Pretax Profit Margin | 0.42 | 0.44 | |
| Operating Profit Margin | 0.41 | 0.43 | |
| Net Profit Margin | 0.34 | 0.36 | |
| Gross Profit Margin | 0.77 | 0.61 |
8 Steps to conduct Halozyme Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Halozyme Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Halozyme Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Halozyme Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Halozyme Therapeutics' revenue streams: Identify Halozyme Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Halozyme Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Halozyme Therapeutics' growth potential: Evaluate Halozyme Therapeutics' management, business model, and growth potential.
- Determine Halozyme Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Halozyme Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Halozyme Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Halozyme Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 134.2 M | |
| Quarterly Earnings Growth Y O Y | 0.546 | |
| Forward Price Earnings | 12.6263 |
Halozyme Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Halozyme Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Halozyme we look at many different elements of the entity such as Halozyme's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Halozyme Therapeutics' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Halozyme Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Halozyme Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Halozyme Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Halozyme Therapeutics' worth.When determining whether Halozyme Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Halozyme Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Halozyme Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Halozyme Therapeutics Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Halozyme Stock analysis
When running Halozyme Therapeutics' price analysis, check to measure Halozyme Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Halozyme Therapeutics is operating at the current time. Most of Halozyme Therapeutics' value examination focuses on studying past and present price action to predict the probability of Halozyme Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Halozyme Therapeutics' price. Additionally, you may evaluate how the addition of Halozyme Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Halozyme Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.546 | Earnings Share 2.1 | Revenue Per Share 6.286 | Quarterly Revenue Growth 0.267 | Return On Assets 0.1189 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.